RxDoctor Payments DataLook up a doctor →

D Cannon, MD

Pulmonary Disease · Jackson, MSNPI 1033103122

Payments from drug & device makers

$10,229in general payments, 2019–2025

Across 538 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$4K
  • AstraZeneca$963
  • Actelion Pharmaceuticals US, Inc.$953
  • Philips North America LLC$543
  • Johnson & Johnson$480
  • Insmed, Inc.$465
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$10,04698%
  • Education$1832%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,229 in reported general payments places this provider in the 65th percentile of 101 pulmonary disease providers in Mississippi.

See all pulmonary disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$573,973
Medicare patients
860
Services billed
5,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan30$379,683
UptraviSelexipag16$354,030
OfevNintedanib Esylate12$155,418
Fasenra PenBenralizumab11$62,444
Trelegy ElliptaFluticasone/Umeclidin/Vilanter89$61,152
XolairOmalizumab12$19,284
Breo ElliptaFluticasone/Vilanterol40$18,719
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,337
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$3,489
Albuterol Sulfate HfaAlbuterol Sulfate58$1,898
Ventolin HfaAlbuterol Sulfate19$1,053
Temazepam12$705
Azelastine Hcl11$558
Clarithromycin11$325
Montelukast Sodium16$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$953$733,71346 claims
Boehringer IngelheimOfev$396$155,41812 claims
GSKTrelegy Ellipta, Breo Ellipta$3,824$79,871129 claims
AstraZenecaBreztri Aerosphere$963$10,33717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 101 pulmonary disease providers in Mississippi.

Other pulmonary disease in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →